Agilis RoboticsTM (Agilis) is revolutionizing endoscopic surgery with its groundbreaking robotic instruments. Co-founder Dr. Jason Y.K. Chan recently completed a successful live animal test on a pig specimen, using the firm’s second-generation device to perform an en-bloc resection of bladder tumor (ERBT) – a precise and safe removal of artificial tumors. The results of the test exceeded expectations, paving the way for a more accurate and efficient way to perform endoscopic surgeries.
Building on the expertise of surgeons from prior experiments, the research team has implemented a range of technical advancements to the original system, dramatically improving the speed and efficiency of the surgery.
Tuned up and ready to go, the 2nd generation prototype system offers streamlined surgical control like never before. With optimized features, this revolutionary system is primed to revolutionize the industry.
The Agilis RoboticsTM system is revolutionizing endoscopic surgery with its cutting-edge surgical robotic solution. This high-tech system includes a set of ultra-flexible robotic instruments, a positioning cart, and a control chair for the surgeon. With a diameter of less than 2.8 mm, the robotic instruments are able to accurately grip and cut away tumor tissue for a complete removal.
The second-generation prototype system has been upgraded with several improvements, making it a more efficient and convenient system. Most notably, the updated positioning cart is 50% smaller than the original, making it incredibly compact and easy to maneuver within the operating room. As a result, this system is more efficient and easier to use than ever before.
The newly developed endoscope holder offers surgeons unparalleled flexibility when it comes to positioning the endoscope and robotic instruments. The holder’s sensor allows for effortless movement with just one hand, while the automatic locking mechanism keeps the unit firmly in place. This revolutionary device not only simplifies the surgical process, but also boosts patient safety by providing a secure and stable platform for precise operations.
This prototype iteration has made significant improvements to both the surgical tools and the overall experience of the surgeon. The surgical field is now more clearly visible and can handle heavier demands, while the electrosurgical knife has been upgraded with a bipolar diathermy that makes tissue cutting more efficient. Further, the controls and mechanical transmission have been fine-tuned for greater precision and responsiveness, and the ergonomics and training simulator have been overhauled for maximum comfort and convenience. These advancements make the entire procedure more intuitive, responsive and user-friendly than ever before.
The company is set to make a major breakthrough in the market for GI diseases, with an upcoming animal trial for upper and lower gastrointestinal (GI) endoscopic submucosal dissection (ESD). This test promises to be an important milestone for the company, showcasing its potential to revolutionize the field.
The company is on the brink of transforming the market for GI diseases with their upcoming animal trial for upper and lower GI endoscopic submucosal dissection (ESD). This groundbreaking test is set to revolutionize the field, providing a major breakthrough in the treatment of these diseases.
As the first internal medicine physician to utilize the system, Dr. Chan not only conducted ev-vivo tissue resection tests but also offered insight into the system’s potential to revolutionize the GI market. He envisions the system’s accessibility in general endoscopy clinics and centers, allowing it to become widely adopted and utilized throughout healthcare institutions.
Agilis RoboticsTM is revolutionizing minimally invasive endoscopic procedures with its intuitive technology, setting a new standard for the industry. From its unmatched intuitiveness to its rapid evolution, Agilis RoboticsTM is transforming the way we experience endoscopic procedures.
In recent years, minimally invasive endoscopic procedures such as EMR and ESD have become increasingly popular for treating submucosal tumors, early cancers, and precancerous lesions in the digestive tract. This is a result of the growing awareness of health risks among the general population. These procedures are highly beneficial for patients as they eliminate external incisions and promote a faster recovery with minimal discomfort. Ultimately, this has led to improved outcomes for those affected by digestive tract diseases.
In recent years, endoscopic minimally-invasive interventional techniques have developed rapidly, revolutionizing the way digestive disorders are treated. This cutting-edge approach offers a more convenient, less invasive alternative to traditional treatments, making it an increasingly popular choice for those seeking relief from digestive issues.
Interventional procedures have become increasingly popular amongst patients due to their minimally invasive nature and shorter hospital stays. By allowing for the complete removal of diseased tissue without compromising the digestive tract’s normal functioning, this approach significantly reduces the risk of post-operative complications such as infection, which are often associated with more invasive surgeries, such as open-heart and open-abdomen surgeries.
Endoscopic surgery offers a wealth of benefits, not least of which is a rapid recovery period and a much shorter stay in the hospital for those who receive the procedure. Not only does it provide a faster recovery time, endoscopic minimally-invasive procedures are more cost-effective, with prices ranging from as low as 20,000 yuan, compared to the 20,000 to 40,000 yuan range of general surgery.
The company took an innovative step in their prototype tests by inviting laypeople with no medical background to observe the process. After a brief introduction to a virtual training simulator, the laypeople got to experience the thrill of tissue dissection in an ex-vivo tissue model.
Visitors were astounded by the capability of the Agilis surgical robot, which, within just 20 minutes of simulator training, could already perform an amazing feat – removing artificial tumors from ex-vivo tissue. With its uncomplicated usage and minimal training requirements, even doctors skilled in endoscopic procedures can quickly pick up the skill. The visitors were filled with optimism for the device’s potential to become commercially available.
The Agilis system is revolutionizing the way surgeons learn and hone their skills for en-bloc tumor resection. By harnessing the power of artificial intelligence, this system uses empirical endoscopic imaging for deep learning to help reduce the learning curve for mastering this procedure. With AI-powered training, even novice surgeons can quickly become proficient at this surgical technique.
Introducing the revolutionary new robotic equipment from Endo Robotics, a US$100 million firm dedicated to revolutionizing endoscopic surgery and making it safer, more efficient, and more precise than ever before. With cutting-edge technology and a mission to save lives, Endo Robotics is leading the way in 21st century medical technology.
Surgical robots are revolutionizing the medical industry in China, and the demand for their use in laparoscopy, orthopedic surgery, neurosurgery, and vascular intervention is growing rapidly. Businesses need to find innovative ways to stay ahead of the competition and break through the technology bottleneck to succeed.
Robotic endoscopic surgery presents an exciting challenge for medical engineers, as they strive to create robots that can fit through the narrow passageways of the human body. With working channels of only 2.8 to 3.7 millimeters in diameter, the robots must be highly flexible yet ergonomically designed to be small enough to fit through these tight spaces. It’s an incredible feat of engineering to make this happen.
Agilis RoboticsTM has revolutionized the world of endoscopic surgery with their groundbreaking surgical robotic device, designed to make procedures more efficient and reduce the learning curve. This revolutionary robotic system seamlessly integrates with existing GI and urological systems, providing total flexibility and outstanding technological achievements. With Agilis RoboticsTM, endoscopic surgery has never been more accessible and efficient.
Endoscopic surgery, a type of natural orifice transluminal endoscopic surgery (NOTES), is different from laparoscopy and requires a unique set of technical abilities. Leading firms such as Johnson & Johnson, Intuitive Surgical, and Medtronic have created their own robotic systems, however none of them use the standard endoscopes and their working channels. At the moment, Chinese scientists are conducting research on NOTES in the bronchial sector, but none of these studies have been approved for use in the country.
The global NOTES robot market is experiencing a staggering 88.2% CAGR growth from 2016 to 2026, and is projected to reach an incredible 12.53 billion yuan by 2026, from just 457 million yuan in 2020.
Agilis RoboticsTM is leading the charge into the revolutionary world of endoscopic surgery robots for the urology and digestive systems. As the first Chinese business to build an endoscopic surgery robot, their product is already taking shape and pre-clinical testing is on the horizon – creating a huge opportunity for growth in the market. Don’t miss out on the incredible opportunity to revolutionize surgery with Agilis RoboticsTM.
Introducing the second-generation prototype of Agilis RoboticsTM—which has optimized the structure and integration of the firm’s flexible robot instruments—the company is now taking the next step to improve robotics control and console’s design and control features. With the aim of enhancing surgical accuracy and efficiency, the company is anticipating the completion of the first human trial within the next two years. It is a promising advance in the field of robot-assisted surgery that is sure to revolutionize the industry.
Agilis RoboticsTM is set to revolutionize healthcare with the advancement of their prototype, which will be delivered to The University of Hong Kong-Shenzhen Hospital for additional testing in the second quarter of 2022. After completing NMPA testing in the third quarter of 2023, the company is poised to launch a PRE-B round of funding with a minimum investment of US$10 million. Furthermore, as an incentive to investors, the company has set up a special Series A+ of US$5 million. Last year’s COVID-19 outbreak was a setback for the company, preventing investors from visiting Hong Kong for test and experience the system in Series A roadshows. However, Agilis RoboticsTM is determined to make their mark and revolutionize healthcare.